Past, Present, and Future Drug Delivery Systems for Antiretrovirals

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.xphs.2016.09.015">http://dx.doi.org/10.1016/j.xphs.2016.09.015</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Author's final manuscript</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sat Apr 13 09:38:46 EDT 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/112335">http://hdl.handle.net/1721.1/112335</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Creative Commons Attribution-NonCommercial-NoDerivs License</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a></td>
</tr>
</tbody>
</table>
Past, present and future drug delivery systems for antiretrovirals

Ameya R. Kirtane\textsuperscript{a,b}, Robert Langer\textsuperscript{a,b,c,*} and Giovanni Traverso\textsuperscript{a,b,d,*}

\textsuperscript{a}Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139

\textsuperscript{b}The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139

\textsuperscript{c}Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139

\textsuperscript{d}Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115

Correspondence:

Correspondence should be addressed to Giovanni Traverso and Robert Langer

Dr. Giovanni Traverso
Division of Gastroenterology
Brigham and Women’s Hospital
75 Francis St, Thorn 14,
Boston, MA 02115
Tel: 617-417-8061
Fax: 617-500-0631
Email: ctraverso@partners.org

Professor Robert Langer
Koch Institute for Integrative Cancer Research, Room 76-661
Massachusetts Institute of Technology
77 Massachusetts Avenue
Cambridge, MA 02139
Tel: 617-253-3107
Fax: 617-258-8827
Email: rlanger@mit.edu
1 Abstract

The human immunodeficiency virus has infected millions of people and the epidemic continues to grow rapidly in some parts of the world. Antiretroviral therapy has provided improved treatment and prolonged the life expectancy of patients. Moreover, there is growing interest in using antiretrovirals to protect against new infections. Hence, antiretrovirals have emerged as our primary strategy in combating the virus. Unfortunately, several challenges limit the optimal performance of these drugs. First, antiretrovirals often require life-long use and complex dosing regimens. This results in low patient adherence and periods of lapsed treatment manifesting in drug resistance. This has prompted the development of alternate dosage forms such as vaginal rings and long-acting injectables that stand to improve patient adherence. Another problem central to therapeutic failure is the inadequate penetration of drugs into infected tissues. This can lead to incomplete treatment, development of resistance and viral rebound. Several strategies have been developed to improve drug penetration into these drug-free sanctuaries. These include encapsulation of drugs in nanoparticles, use of pharmacokinetic enhancers, and cell-based drug delivery platforms. In this review, we discuss issues surrounding antiretroviral therapy and their impact on drug efficacy. We also describe various drug delivery-based approaches developed to overcome these issues.

Key words
Nanoparticles, controlled release, blood brain barrier, injectables
2 Introduction

Despite significant progress in the understanding, treatment and prevention of the human immunodeficiency virus (HIV), 2 million new cases of HIV infection were recorded in 2014.\textsuperscript{1} There were ~36 million people living with HIV infection and ~1.2 million acquired immunodeficiency syndrome (AIDS)-related deaths in 2014.\textsuperscript{1} The prevalence of HIV infection is disproportionately high in Africa.\textsuperscript{2} There are ~25 million HIV-infected individuals in Africa, accounting for 70% of the HIV infected population.\textsuperscript{3} In the absence of a cure, these numbers are bound to increase, suggesting that we are not past the epidemic yet. However, there are many drugs available for the management of the disease. Optimum use of these drugs will enable control of the epidemic and improve disease-associated morbidity and mortality.

The first report of HIV-AIDS appeared in a morbidity and mortality weekly report in 1981.\textsuperscript{4} The five patients described in this report were homosexual men living in the Los Angeles area, who presented with \textit{Pneumocystis carinii} pneumonia, and other infections.\textsuperscript{4} Similar occurrences, coupled with Kaposi's sarcoma, were later reported in New York as well.\textsuperscript{5} However little was known about the cause of this mysterious disease. In 1983-84, groundbreaking work from the labs of Montagnier and Gallo showed that it was a retrovirus, later named the HIV-1, which was responsible for this disease.\textsuperscript{6-8} Subsequently, the HIV-1 main type (M-type) of the virus was associated with millions of infections around the world. Other types of HIV-1 such as N, O and P have also been identified.\textsuperscript{9} Another virus, which is morphologically similar to HIV-1, also causes AIDS and has been termed the HIV-2. The probability of disease development with HIV-2 is less than that with the HIV-1\textsuperscript{10} and the latter is the more predominant virus.\textsuperscript{9}

Following the isolation of the virus, research in this area progressed at a swift pace.\textsuperscript{11-13} In 1987, zidovudine was the first antiretroviral (ARV) drug approved for the treatment of HIV.\textsuperscript{14} After almost three decades, today, there are nearly 30 drugs approved for the treatment of HIV infection.\textsuperscript{15-17} Interestingly, today, the life expectancy of an HIV infected individual diagnosed early and having ready access to medical services is comparable to that of a healthy individual.\textsuperscript{18} Moreover, HIV drugs can now be used as a preventative measure to protect healthy individuals who are at a high risk of encountering the virus.\textsuperscript{19-21} This approach, referred to as pre-exposure prophylaxis (PrEP), promises to have a significant impact on the spread of the disease and potentially protect millions of people around the world.

Despite these successes, several challenges remain concerning the management of the disease. We highlight here two factors, which we believe, are central to the performance of HIV drugs. The first is that of patient adherence to the therapeutic regimen. Finding alternatives that enhance patient adherence can allow for more effective application of anti-HIV drugs. The second limitation with current ARVs is their poor penetration into several tissues. Improving drug penetration into these tissues may provide an opportunity for the complete elimination of virus, reduced dosing and/or improved therapeutic efficacy. In this review, we describe drug delivery interventions to
address these two problems, poor adherence to therapy, and unfavorable biodistribution of drugs.

3 Antiretroviral drugs for the treatment and prevention of HIV infections

Before the discovery of ARV drugs, patient mortality in the HIV infected population was high due to the development of AIDS. However, with the discovery of several potent ARV drugs, there is tremendous improvement in patient life expectancy and their quality of life. Moreover, in the absence of a viable HIV vaccine and limited effectiveness of behavioral interventions, ARV drugs have emerged as an important strategy for the prevention of HIV infection as well. Consequently, ARV drugs have been central to our efforts in combating HIV. In this section, we provide an overview of various ARV drugs approved for therapy.

3.1 Life cycle of the HIV

The life cycle of the HIV is integral to the understanding of antiretrovirals. We outline here the various steps of the viral life cycle starting from infection of a host cell to the formation of a new virus.

One of the primary targets of HIV are CD4+ T cells. The viral gp120 protein engages chemokine receptors, mainly the CXC chemokine receptor 4 (CXCR 4) or the CC chemokine receptor 5 (CCR 5), on the surface of T cells. This process triggers a conformational change in the gp120 protein and leads to the exposure of the gp41 protein. This enables the fusion of viral cell membrane with the host cell membrane allowing entry of viral contents (reverse transcriptase complex) into the host cell. Reverse transcriptase converts the viral RNA into double stranded proviral DNA. The proviral DNA is then transferred into the nucleus and integrated into the host DNA via the enzyme integrase. Using host mechanisms, the viral DNA is transcribed and later translated into precursor polyproteins. The Gag polyprotein brings about the assembly of viral components such as polyproteins and nucleic acids at the host cell membrane. This is followed by the budding of viral particles from the cells and their maturation, enabling them to infect new cells.

3.2 Antiretroviral drugs

Zidovudine, the first approved antiretroviral, is a competitive inhibitor of reverse transcriptase. Zidovudine is a structural analogue of thymidine and upon three successive intracellular phosphorylations, can be incorporated into the growing cDNA chain. However, due to the lack of a 3’-hydroxyl group it acts as a chain terminator and prevents the formation of proviral DNA. Following the clinical success of zidovudine, several drugs (such as didanosine, zalcitabine, stavudine, and lamivudine) with a similar mechanism of action were approved. These drugs are termed nucleoside reverse transcriptase inhibitors (NRTIs).

Nucleotide reverse transcriptase inhibitors (NtRTIs) are another class of competitive inhibitors of reverse transcriptase. Their mechanism of action is similar to that of NRTIs.
However, these drugs contain an additional phosphate group, and require only two additional phosphorylations to produce the active drug form. Due to the altered attachment of phosphorus, these drugs are less vulnerable to esterase activity and pyrophosphorolysis than NRTIs. Tenofovir, a NtRTI, has now become an integral part of several ARV drug regimens.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are allosteric inhibitors of reverse transcriptase. These drugs bind at a site ~10 Å from the catalytic site of the enzyme and effect a conformational change in the enzyme inhibiting its normal catalytic activity. Currently, there are 5 NNRTIs approved for use in HIV treatment, with efavirenz being one of the most commonly prescribed drug. Unfortunately, NNRTIs are prone to rapid development of resistance stemming from mutations in the drug-binding pocket of the enzyme. Newer NNRTIs such as rilpivirine show activity against multiple viral strains, and hold immense promise for HIV therapy.

Integrase inhibitors block the integrase-mediated incorporation of proviral DNA into the host genome. Integrase works via a two-step process to incorporate viral DNA into the host genome. These two steps are termed 3′-processing and strand transfer. Integrase inhibitors work predominantly by inhibiting the second step of this process. Raltegravir was the first approved integrase inhibitor, followed by dolutegravir and elvitegravir.

The HIV-1 protease is key to viral multiplication and is distinct from human proteases. Protease inhibitors block the viral protease, which is responsible for the cleavage of viral proteins and maturation of viral particles. Protease inhibitors such as saquinavir, ritonavir, indinavir, contain an amide bond resembling the phenylalanine-proline sequence found in gag-pol proteins of the virus allowing their binding to the viral protease. Newer protease inhibitors such as tipranavir do not contain the peptide-like bond but still efficiently inhibit the viral protease by forming strong hydrogen bonds with the active site of the enzyme.

The first step of viral infection is its entry into CD4+ cells. Drugs that block this process are termed entry inhibitors and have been the subject of extensive research. Viral entry is mediated by the binding of viral gp120 to the CCR5 or CXCR4 chemokine receptor on the surface of CD4+ cells. Maraviroc is an allosteric inhibitor of CCR5 and blocks viral entry. Maraviroc is used only in patients infected with the CCR5 tropic virus, and is not recommended as a first-line treatment. Inhibition of gp41 protein can also mediate antiviral activity. Enfuvirtide, the first approved viral entry inhibitor, elicits its activity by binding gp41 and altering its folding.

While the use of a single HIV drug can limit viral replication, emergence of resistance is common. This finding underscored the need for therapeutic regimens that prevented, or at least delayed, the development of resistance. In their seminal work, Gulick et al. showed that the combination of zidovudine, lamivudine and indinavir controlled viral load better than zidovudine-lamivudine combination or indinavir alone. Following this study,
the use of a three-drug combination therapy (usually containing drugs from two different drug classes) has been the backbone of HIV therapy. This three-drug combination therapy generally consists of two NRTIs and a third drug from a different class. This third drug can be either a NtRTI, integrase inhibitor or a protease inhibitor combined with a pharmacokinetic enhancer.\textsuperscript{50} Inhibiting the virus at different stages in its life cycle reduces the development of resistance. Additionally, it is suggested that the use of NNRTIs and PIs leads to unique form of intermolecular cooperativity resulting in greater activity with the multidrug combination.\textsuperscript{51} There are currently 6 recommended ARV combinations viz. dolutegravir/abacavir/lamivudine, dolutegravir/tenofovir disoproxil fumarate (TDF)/emtricitabine, elvitegravir/cobicistat/tenofovir alafenamide fumarate (TAF)/emtricitabine, elvitegravir/cobicistat/TDF/emtricitabine, raltegravir/tenofovir/emtricitabine, and darunavir or ritonavir/TDF/emtricitabine.\textsuperscript{50}

The rapid development of HIV drugs and their impact on the progression of the epidemic is a significant achievement for the scientific community. The introduction of ARV therapy has had a profound effect on the management of the disease, life style and life expectancy of HIV infected individuals. A study by Crum et al. evaluated the mortality rate in HIV patients in the US with open access to medical care and low rates of co-infection in the pre- and post-ARV therapy era.\textsuperscript{22} In the pre-ARV therapy era, the annual mortality rate peaked at ~10\% in 1995. However, the annual mortality rate in the post-ARV therapy era was as low as 0.2\%.\textsuperscript{22} Another study analyzed the life expectancy of HIV infected patients in North America and Europe.\textsuperscript{52} In the early ARV therapy era (1996-1999), the life expectancy of a 20-year-old patient was ~36 years, while in the late ARV therapy era (2003-2005), life expectancy increased to ~49 years.\textsuperscript{52} Recently similar results were reported; suggesting that certain populations of HIV infected individuals may have comparable life expectancies to healthy individuals.\textsuperscript{18} While these and other studies highlight the impact of combination therapy on patient morbidity and mortality, it should be noted that the choice of patient population and the availability of resources plays a significant role in affecting the outcomes of these studies. Nevertheless, these studies highlight that if appropriately used, ARV therapy can treat HIV infection effectively.

Over the last 30 years, HIV drugs have become more effective in treating different subtypes of HIV-1 viruses and have an improved safety profile as well. It has been realized that HIV drugs can be used in healthy individuals as a means of prevention. This strategy, termed PrEP, has gained attention recently, and may play a major role in the eradication of the disease.\textsuperscript{19,21}

4 \hspace{1cm} \textbf{Role of drug delivery in improving efficacy of antiretrovirals}

The introduction of ARVs has revolutionized the management of the disease. Yet, the epidemic continues to affect millions of people around the world. Several factors contribute to our inability to eradicate the disease. In the following sections, we highlight two issues central to the success of HIV therapy that can be addressed by drug delivery. First, we discuss the lack of patient compliance to ARVs, its effect on their efficacy and
the role of drug delivery in improving patient adherence. Second, we highlight the role of viral reservoirs and sanctuaries in the failure of ARV therapy. While several other obstacles to HIV therapy remain, we discuss here only those that can be influenced significantly by drug delivery interventions.

4.1 Improving patient adherence to therapy

Complete elimination of the virus with combination ART has proven unsuccessful. However, viral load can be controlled over extended periods with continuous therapy. Consequently, life-long therapy is imperative for managing the disease.53 Missing a dose can result in viral rebound or development of resistance to drug therapy.54 The efficacy of HIV PrEP also relies on the presence of therapeutic levels of drug at the site of viral entry. Hence, adherence is key to the success of ARV therapy.

Adherence to self-administered medication is low across disease areas. Electronic medication monitors indicate that one-half of the patient population takes drug holidays, and one-sixth take few to no doses of drug. Even under the controlled settings of clinical trials, adherence rates as low as ~43% have been reported.55,56 The prevalence of this problem in the HIV space was highlighted during recent clinical trials.57 The iPREX team evaluated the efficacy of a combination of tenofovir and emtricitabine to prevent HIV infection in a MSM (men having sex with men) population and transgender women.19 Infection rate in the treated group was 47% lower in comparison with the placebo group. However, in a patient population recording ≥90% pill usage, the effectiveness was as high as 73%. Unfortunately, ≥90% pill use was observed only during half of the visits.19 The CAPRISA trial tested the efficacy of a once-daily vaginal gel of tenofovir in sexually active women in South Africa.58 The trial showed remarkable success with an overall effectiveness of ~39% in the treated population vs. placebo. Interestingly, the effectiveness of the gel in patients having an adherence of >80% was significantly higher (~54%).58 The VOICE59 and FEM-PrEP60 trials assessed the protective efficacy of various formulations of either tenofovir alone or a combination tenofovir and emtricitabine in adult women. Both trials were unable to establish treatment efficacy, and low adherence was implicated for this lack of effectiveness. For example, in the VOICE trial, more than half of the population did not have any detectable drug levels in the blood through the entire trial. These studies highlight the importance of patient compliance for the success of the therapy.59

There are several factors responsible for poor adherence to treatment. Cost, availability, dosing regimens, side-effects of the drugs, and socio-economic factors surrounding the use of anti-HIV drugs play an important role in affecting patient behavior.61-63 Several interventions (such as patient counselling, reminders, financial incentives etc.) have been used for overcoming these barriers. These approaches have been reviewed elsewhere64,65 and will not be discussed here.

The simplicity of the therapeutic regimen significantly affects patient acceptability of the medication.62,66 Unfortunately, dosing regimens of HIV drugs can be particularly complex and may involve multiple pills. The complexity of the therapeutic regimen is
highlighted by that of pericoital vaginal gels. For example, the vaginal gel tested in the CAPRISA trial was supposed to be used 12 hours prior to and within 12 hours of a sexual act, and no more than twice in 24 hours. This so-called BAT24 strategy may be difficult to practice for a few reasons. First, the spontaneity of the sexual act may prevent appropriate implementation of the regimen. Second, maintaining privacy may not be possible, ultimately discouraging the patient from using the product. Another factor limiting the use of HIV drugs is the multiplicity of pills. Fixed dose combination pills that contain two or more drugs in a single unit do ease this issue. Patients on fixed dose combination pills have a 26% reduction in non-adherence as compared to those taking the individual drug components. Though several combination pills (such as Stribild, Triumeq, Trizivir, Genvoya etc.) are now available, the patient is required to take at least one pill every day for the rest of their life. This may lead to pill fatigue and ultimately lapse in treatment or protection. Improvements in drug delivery may help address these issues and hence overcome one of the problems central to HIV therapy. In the next section, we highlight elegant drug products that may facilitate drug use and improve the overall outcomes with HIV therapy.

4.1.1 Vaginal rings

Sexual intercourse remains the major route of viral transmission. Studies show that the risk of viral transmission from an infected man to a healthy woman are higher than that from an infected woman to a healthy man. In a European multicenter study, the rate of HIV transmission in 563 heterosexual couples with one infected partner was analyzed. During this study, 12% of the male partners and 20% of the female partners were infected, indicating that the risk of male-to-female transmission was ~1.9-fold higher than female-to-male transmission. Social and cultural factors related to sexual intercourse in sub-Saharan Africa worsen this situation for women. Consequently, women remain more susceptible to HIV infection as compared to men. Therefore, interventions initiated and controlled by women may have a significant impact on the spread of the disease.

Vaginal gels loaded with anti-HIV drugs have been used for PrEP. Although this strategy has found some clinical success, lack of patient compliance has questioned its practicality. Several factors limit patient acceptability of vaginal gels. High turnover of vaginal fluids results in diminished residence for most drugs. Consequently, these gels need to be used at least once daily. Second, low viscosity of gels results in leakage of the gel from the vaginal cavity and an unpleasant patient experience. Finally, some gels require pre- and/or post-coital application, which is often not practical. As a result, patient acceptability of, and hence compliance to, vaginal gels is often low.

Vaginal rings are polymeric devices loaded with the drug of choice, which the patient places in the vagina for an extended period. Vaginal rings loaded with female hormones have been used with great success for birth control. These systems have proven successful for the delivery of a wide variety of drugs including small lipophilic molecules such as steroids and large hydrophilic peptides such as leuprolide. These factors have spurred significant interest in the development of vaginal rings for the delivery of anti-HIV
drugs. A vaginal ring for the delivery of an NNRTI, dapivirine, is currently in late clinical trials and holds promise as a preventative strategy. In a recent study, a monthly ring containing dapivirine showed better protection than placebo controls.\textsuperscript{82} In this section, we provide an overview of the various technologies and formulations used in the development of vaginal rings.

Two materials have been central to the development of vaginal rings containing anti-HIV drugs, silicone and polyurethane.\textsuperscript{78} Silicone offers the advantage of low processing temperature, however lacks mechanical stiffness. Polyurethanes are thermosetting polymers that are usually processed at high temperatures. However, polyurethanes provide significantly better mechanical performance essential for placement of the device and in vivo stability.\textsuperscript{83}

Malcolm et al. described the fabrication and characterization of one of the first vaginal rings containing dapivirine.\textsuperscript{84} The ring was a reservoir-type device consisting of a drug loaded silicone core and an external drug-free silicone sheath. The ring was \textasciitilde 10 g in weight and had an overall diameter of 55 mm. \textit{In vitro} drug release experiments showed that after an initial burst lasting 2-3 days, drug release followed a near zero-order profile. The burst release was attributed to the presence of drug in the non-medicated sheath (an artifact of the fabrication process, confirmed using Raman spectroscopy).\textsuperscript{84,85} It was later shown that the rate of drug release could be modified by addition of excipients such as lactose.\textsuperscript{86} The safety and pharmacokinetics of dapivirine rings were evaluated in healthy individuals. Two rings containing 25 mg and 200 mg of dapivirine each were tested.\textsuperscript{87} In both rings tested, drug concentrations in vaginal fluids around the introitus and cervix were greater than the EC90 of the drug. These concentrations were reached within 4 h and were sustained up to 7 days (the last day of the study).\textsuperscript{87} A study by Nel et al. analyzed the pharmacokinetics of dapivirine following administration in reservoir- and matrix-type devices.\textsuperscript{88} Release from a matrix type device ($t_{\text{max}}$ – 1 day) was faster than that from reservoir-type device ($t_{\text{max}}$ – 5 days). At the end of the 28-day study, \textasciitilde 42% of the drug was released from the matrix type device, while only \textasciitilde 3% of the drug was released from the reservoir-type device. However, dapivirine concentrations in the vaginal fluid were higher than its \textit{in vitro} EC90 value in patients treated with both devices.\textsuperscript{88}

Extensive work in the Kiser lab has evaluated the use of polyurethane for the formation of vaginal rings.\textsuperscript{89-92} Gupta et al. constructed matrix-type vaginal rings consisting of polyurethane loaded with dapivirine.\textsuperscript{83} Dapivirine was released at a near-zero order rate and the rate of drug release depended on the initial drug loading. Kaur et al. developed a poly(ester-co-ether) incorporated into the polyurethane backbone to provide it with biodegradable properties.\textsuperscript{93} The mechanical properties of rings made with this polymer were similar to those of the commercially used EVA ring.\textsuperscript{93}

Vaginal rings can also be used for the simultaneous delivery of drugs with significantly different physicochemical properties. Johnson et al. developed a device for the delivery of dapivirine (clogP\textasciitilde 6.3) and tenofovir (clogP\textasciitilde 2.3).\textsuperscript{94} One half of the vaginal ring was made of a water-swellable polyurethane and was loaded with the hydrophilic drug, tenofovir.
The second half of the device was constructed with a non-water swellable polymer and was loaded with dapivirine. The water swellable polymer allowed entry of water into the polymer matrix, dissolution of the drug and hence improved drug release. When loaded into the non-water swellable polymer, tenofovir was not released at all. In another study, two types of poly(ether urethane)s were used for the construction of the vaginal ring. A hydrophobic segment was made of poly(tetramethylene oxide) and a polyurethane, and was loaded with the hydrophobic drug levonorgestrol. The other segment in the ring was made of a combination of poly(ethylene glycol), poly(tetramethylene oxide) and polyurethane, and was loaded with tenofovir. Addition of poly(ethylene glycol) increased the hydrophilicity of the polymer and allowed efficient release of tenofovir. The release of levonorgestrol was analyzed in a rabbit model, and was found to be sustained for ~90 days. This device can potentially be used for contraception and HIV prevention. Simultaneous delivery of drugs from silicone rings has also been demonstrated. Moss et al. and Baum et al. developed silicone rings fitted with compressed plugs of tenofovir and acyclovir coated with a layer of poly(lactide) for their sustained delivery. Initial proof-of-concept studies were carried out in a rabbit and sheep model.

In summary, vaginal rings offer a simpler alternative to vaginal gels, and show greater patient acceptability. Given the location of these rings such delivery systems stand to provide a platform for the delivery of a broad range of anti-infective that may limit the transmission of sexually transmitted diseases. A variety of drugs can be loaded into these devices and sustained release over different time periods can be obtained.

4.1.2 Sustained systemic delivery of antiretrovirals

The multiplicity and frequency of pill use in HIV is high. Reducing the frequency of dosing can enhance patient compliance and improve therapeutic efficacy. Recently, there has been significant interest in the development of long-acting injectable antiretrovirals. These products are intended to be used for PrEP in individuals at high risk of encountering the disease and possibly for maintenance therapy in patients infected with HIV. Nanocrystals of the drug are administered intramuscularly, and the drug is absorbed slowly from this site. Rate of drug absorption is affected by the solubility of drug in physiological fluids and blood supply to the muscles. Two drug formulations of rilpivirine and cabotegravir are currently in late clinical development. We discuss here results from preclinical studies and clinical trials.

Rilpivirine nanoparticles were synthesized by wet milling the drug with surfactants such as D-α-tocopherol polyethylene glycol 1000 succinate (vitamin E TPGS) or poloxamer 338. Formulations with three different particle sizes (200, 400 and 800 nm) were obtained. Their pharmacokinetics upon intramuscular and subcutaneous administration were evaluated in dogs. Subcutaneous administration of a 5 mg/kg dose of rilpivirine led to detectable drug concentrations in the blood for up to 6 months. Intramuscular administration led to a more rapid absorption and faster elimination as compared to the subcutaneous route. This was likely due to the higher vascularity of the muscles as compared to the skin. Additionally, 200 nm nanoparticles had the fastest
absorption owing to their higher surface area to volume ratio. Brain-to-plasma and spleen-to-plasma concentration ratios were found to be ~2 during the study. Concentrations in the lymph node were ~4-fold higher than the plasma. In contrast, concentration in the draining lymph node was ~100-fold higher than the plasma.\textsuperscript{104,105}

A series of clinical studies have evaluated the safety, tolerability and pharmacokinetics of rilpivirine nanoparticles.\textsuperscript{106} In one such study (C146 study), rilpivirine was administered to six healthy subjects at doses of 200, 400 and 600 mg. The injections were generally well tolerated, with the intramuscular administration considered favorable as compared to subcutaneous injection. In another study, the pharmacokinetics of rilpivirine in healthy individuals were monitored after 300, 600 and 1200 mg intramuscular dose.\textsuperscript{107} Upon intramuscular injection, the drug had a $t_{\text{max}}$ of 5-8 days in plasma and cervicovaginal fluid, and ratio of concentrations in the cervicovaginal fluid and plasma was ~0.8 throughout the study. Half-life of the drug in plasma ~40 days. The authors evaluated the ex vivo efficacy of rilpivirine in cervicovaginal lavage 28 and 56 days post dose. Cervicovaginal lavage from patients treated with 1200 mg dose were effective against the virus.\textsuperscript{107} A phase II study is currently underway to determine the safety and tolerability of a 1200 mg dose administered once every 8 weeks.\textsuperscript{106}

Cabotegravir is a potent integrase inhibitor and a long acting injectable formulation of cabotegravir is being actively pursued.\textsuperscript{103} The long acting formulation of cabotegravir was synthesized by wet milling the drug with polysorbate 20 and poly(ethylene glycol) 3350. The nanoparticles are ~200 nm in diameter and are being developed for intramuscular use.\textsuperscript{103}

The effectiveness of long acting cabotegravir has been established in several studies in macaques. In one study, animals were treated intramuscularly with various doses of cabotegravir nanoparticles, and the plasma concentration of the drug was measured.\textsuperscript{108} In the group treated with a 50 mg/kg dose, plasma concentrations of cabotegravir exceeded 4 times the protein adjusted IC90 (usually considered the lower limit of drug concentration that is protective) for 4 weeks. Consequently, in an efficacy study, animals were treated with two doses of the drug (50 mg/kg) administered every 4 weeks. Treated animals were completely protected from weekly rectal viral challenges. On the other hand, all placebo treated animals were infected after 8 viral challenges.\textsuperscript{108} Two studies analyzed the efficacy of long acting cabotegravir in macaque models of vaginal infection. Pigtail macaques were exposed to 22 doses of 50x TCID$_{50}$ (i.e. 50 times median tissue culture infective dose) viral particles over 12 weeks.\textsuperscript{109} All animals in the placebo group were infected after 20 viral doses. Animals that received prophylactic cabotegravir were protected through the entire study. In a similar study in rhesus macaques, animals were exposed a higher dose of the virus (300x TCID$_{50}$ viral particles).\textsuperscript{110} In this study, 2 out of the 8 animals treated with cabotegravir were infected with the virus. Infection was likely due to a high viral dose, and low vaginal drug penetration.

The safety and pharmacokinetics of long-acting cabotegravir have been evaluated in healthy individuals.\textsuperscript{111} The drug is generally well tolerated with the major complaint being
pain at the injection site. When administered as a split injection, a 400 mg and 800 mg dose maintain plasma concentrations above 4 times the protein adjusted IC90 value for at least a month. The half-life of the long acting drug is ~25-54 days while immediate release formulations have a half-life of ~40 hours.\textsuperscript{111}

With the development of two long acting drug formulations from two different drug classes, there is a possibility to use them as a treatment option as well. If successful, this would be the first long acting antiretroviral treatment requiring once-a-month dosing. Initial studies in healthy volunteers have demonstrated tolerability of the drugs at doses as high as 400 mg cabotegravir and 1200 mg rilpivirine administered simultaneously.\textsuperscript{112} Long acting injectable formulations of nevirapine and raltegravir are also being pursued.\textsuperscript{113,114}

Tenofovir alafenamide fumarate (TAF) is a novel prodrug of tenofovir, with favorable safety and potency.\textsuperscript{115} Consequently, there is tremendous interest in developing TAF for PrEP. For these purposes, current clinical trials are investigating the use of a once daily oral pill of TAF. However, a sustained release formulation of TAF is an attractive alternative. Similar to rilpivirine and cabotegravir, very low doses of TAF are required for potent HIV inhibition. However, unlike rilpivirine and cabotegravir, TAF has a high water solubility. Thus achieving sustained release from micronized TAF only is unlikely, and a rate controlling polymer may be required for achieving the desired pharmacokinetics. Addition of excipients limits the dose that can be administered with a single injection, making injection an impractical strategy for delivering TAF.

Recently, the preclinical development of an implantable device for the sustained delivery of TAF was reported.\textsuperscript{116} The device is a hollow cylindrical silicone scaffold (40 mm length x 1.9 mm diameter) filled with solid TAF. The walls of the device have 14 holes (1 mm diameter) covered with heat treated poly(vinyl alcohol), which likely controls the rate of drug release. Upon intradermal implantation of the device in dogs, sustained concentrations of tenofovir were observed in the blood. The active metabolite (tenofovir diphosphate) was detected in peripheral blood mononuclear cells for up to 45 days.\textsuperscript{116} These preclinical data show great promise for application of TAF as PrEP.

In summary, long acting formulations of anti-HIV drugs are being actively pursued. The infrequent administration of these products may improve patient compliance and allow for better therapeutic and protective efficacy.\textsuperscript{101,102}

4.2 Elimination of viral reservoirs and sanctuaries

Upon commencement of ARV therapy, there is a phase of rapid decline in viral load followed by a phase of slower decrease. Unfortunately, complete elimination of the virus with ARV therapy is not possible.\textsuperscript{53} While the underlying mechanism for this is not completely understood, the establishment of viral reservoirs\textsuperscript{53,117,118} and sanctuaries\textsuperscript{118-120} early on during infection are often implicated. Viral reservoirs are cellular or anatomical locations that harbor low levels of quiescent, yet replication-competent virus.\textsuperscript{121} The kinetics of viral decline in these spaces is significantly slower than that in the plasma compartment.\textsuperscript{53,121,122} Consequently, longer durations of therapy are required to eliminate
the virus. Viral sanctuaries are foci that receive sub-therapeutic drug concentrations. In this section, we describe major viral reservoirs and sanctuaries, and the role of drug delivery in overcoming these barriers.

CD4+ T cells are an important target for the HIV and an important cellular reservoir as well. Upon entry into activated CD4+ T cells, the viral cDNA is integrated into the host genome and is replicated along with it. This results in the production of large number of viral particles and eventually causes death of the host cell. However, upon infection of a resting CD4+ T cell, the virus enters into a non-productive phase, termed latency. Latency can arise before or after integration of the viral DNA into the host genome. Pre-integration latency arises from the blockade of reverse transcription or nuclear translocation. Alternately, post-integration latency results from a reduced rate of transcription of the viral genome after it has been integrated into the host genome. In both cases, due to the lack of production of viral particles, the CD4+ T cells are viable and carry virus capable of causing a relapse.

Monocytes and macrophages represent another key viral reservoir. Interestingly, the nature of reservoirs in macrophages is very different from that in CD4+ T cells. Macrophages are characterized by the presence of a large number of viral particles. However, the presence of these viral particles does not have a cytopathic effect on these cells. Moreover, infected macrophages have been implicated in the dissemination of virus into central nervous system (CNS), genitourinary, gastrointestinal and respiratory tracts. This enables establishment of the so-called 'anatomical viral reservoirs' at these sites. These phenomena make macrophages extremely important targets for therapeutic intervention.

Other cellular reservoirs include follicular dendritic cells, NK cells and B cells. The role of these cells in viral persistence has been discussed in detail elsewhere.

Given the role of leukocytes in viral pathogenesis, the lymphoid tissue serves as an important anatomical reservoir for the HIV. Several factors contribute to this effect. The density of immune cells is much larger in lymphoid tissues than in peripheral circulation. Additionally, antigen presenting cells and T lymphocytes are in close contact in the lymph nodes. Finally, lymphocyte activation, and hence viral transcription, occurs efficiently in lymphatic tissues.

The penetration of the virus into spaces that are inaccessible to drug poses a major challenge for ARV therapy. One such viral sanctuary is the CNS. The virus gains entry into the brain via infected macrophages. The CNS is separated from general circulation by the blood brain barrier, which is a series of endothelial cells connected via tight junctions. The blood brain barrier is a physical barrier, which reduces penetration of protein-bound and hydrophilic drugs into the CNS. Additionally, efflux transporters [such as P-glycoprotein (P-gp)] in the blood brain barrier also limit the brain uptake of several drugs. For example, protease inhibitors are substrates of P-gp. The brain penetration of indinavir, nelfinavir, saquinavir and amprenavir was ~10-30-fold higher in
P-gp knockout mice as compared to wild type mice. Reduced drug concentrations in the brain have been associated with poor prognosis and disease progression. In an analysis of the then approved HIV drugs, Letendre et al. found that poor brain penetration of the drug resulted in reduced control of the viral load in the CSF.

These findings have driven the development of various technologies for the improved delivery of drugs to macrophages, lymphocytes and the CNS. In the next section, we provide an overview of various systems designed to target drugs to these regions.

4.2.1 Strategies to enhance drug delivery to viral reservoirs

4.2.1.1 Macrophages

A significant body of work has been dedicated to increasing the delivery of drugs to macrophages. The use of nanotechnology has been central to these efforts. The use of these nano-sized carriers is especially popular for the delivery of chemotherapeutics, where because of their size, nanoparticles preferentially accumulate within solid tumors. The use of nanocarriers in HIV therapy arises from their interaction with cells of the mononuclear phagocytic system (MPS). Upon systemic injection of nanocarriers, vascular proteins are adsorbed onto their surface. This process, termed opsonization, triggers the uptake of nanoparticles by macrophages. As a result, tissues housing macrophages, such as liver, spleen and lungs, often receive high doses of nanoparticles. This can allow for preferential delivery of drugs to macrophages.

Early proof-of-concept studies evaluating macrophage uptake and targeting of nanoparticles were carried out with poly(hexylcyanoacrylate) nanoparticles. Schäfer et al. showed that both, healthy macrophages and those infected with the HIV rapidly took up the nanoparticles in vitro. Primary macrophages isolated from HIV infected patients also retained their phagocytic activity, albeit to a slightly reduced extent, as compared to macrophages isolated from healthy patients. The same group later explored the efficacy of poly(hexylcyanoacrylate) nanoparticles loaded with a protease inhibitor, saquinavir, in HIV-infected monocyte-macrophage (Mo-Mac) cells. The nanoparticulate formulation was ~10-fold more potent as compared to the free drug. In a separate study, the biodistribution of zidovudine-loaded poly(hexylcyanoacrylate) nanoparticles was characterized in rats. Upon nanoparticle treatment, drug concentration in MPS organs such as liver, spleen and lungs, was found to be 2-10-fold higher as compared to the free drug. Higher drug concentrations in these tissues was attributed to the higher uptake of nanoparticles by macrophages. A similar strategy was used for the delivery of zidovudine to macrophages and mucosal tissue in the gastrointestinal tract. Zidovudine was loaded into poly(isohexylcyanoacrylate) nanoparticles and delivered orally in rats. Nanoparticle-based therapy resulted in 3-4-fold higher drug concentrations in the Peyer’s patches and mucosa as compared to free drug.

Magnani et al. developed a novel cell-based strategy for the selective delivery of drug to macrophages. In this work, zalcitabine was encapsulated into erythrocytes by
hypotonic dialysis. The erythrocyte membrane was treated with zinc chloride and bis(sulfosuccinimidyl)suberate, leading to a clustering of transmembrane proteins (band 3) in erythrocytes. This resulted in increased IgG adsorption and macrophage uptake of the erythrocytes. In a mouse model, erythrocyte loaded zalcitabine showed improved activity in comparison with saline controls. A similar strategy was later used for the delivery of a prodrug of adefovir. In vitro analysis showed that adefovir loaded in erythrocytes was more potent compared to adefovir solution in a HIV-infected macrophage model.

4.2.1.2 Lymph nodes

Lymph nodes play an important role in orchestrating immune responses and are a major viral reservoir. Hence, achieving high drug concentrations in the lymph node is essential for optimal therapeutic activity. However, this is often not the case. For example, indinavir concentration in lymph node mononuclear cells was 20-30% of that in peripheral blood mononuclear cells.

To improve lymph node targeting, Kinman and colleagues synthesized lipid-drug complexes of indinavir with phosphatidylcholine and cholesterol. Subcutaneous injection of indinavir-lipid complex in macaques led to a significantly higher drug accumulation in the various lymph nodes. Drug concentrations in lymph nodes were 3-30 fold higher than in peripheral circulation. Lipid-associated indinavir also showed improved efficacy as compared to drug in solution. The mechanism for higher lymphatic accumulation of the lipid nanocarriers was not investigated. However, it was suggested that lymphatic targeting was likely an effect of ‘lymphatic first pass’, where nanocarriers upon subcutaneous administration drained into the lymphatic vessels before entering systemic circulation.

Lipid-based nanocarriers have been shown to encapsulate a combination of ARVs such as lopinavir, ritonavir and tenofovir. While the encapsulation efficiency of the hydrophilic tenofovir was only ~10%, hydrophobic drugs such as lopinavir and ritonavir were loaded efficiently into these systems (encapsulation efficiency of ~90%). Subcutaneous administration of the nanoparticle formulation resulted in improved lymph node delivery of lopinavir (~1000-fold) and ritonavir (~50-fold) as compared to the drugs in solution. Tenofovir levels in the lymph node were generally unaffected by this formulation strategy.

The Bergeron group developed a liposomal formulation targeted to HLA-DR4 receptor, which is commonly upregulated on the cell surface of activated lymphocytes and monocytes. In a mouse model, subcutaneous delivery of targeted liposomes led to improved concentrations in the draining as well as distant lymph nodes. Sterically stabilizing these liposomes with poly(ethylene glycol) improved their accumulation in distant lymph nodes even further. It was later shown that indinavir loaded HLA-DR4-targeted liposomes showed 20-100-fold higher accumulation in lymph nodes in comparison with indinavir solution.
4.2.1.3 Central nervous system

Zidovudine is a polar molecule with poor brain accumulation. In a clinical study, cerebrospinal fluid: plasma concentration ratio for zidovudine was only 0.02. Poor drug penetration into the brain can be attributed to its low partition coefficient. Transport of the drug across the blood brain barrier can be improved by increasing its hydrophobicity. To increase the hydrophobicity of zidovudine, its primary hydroxyl group was modified with an acyloxy alkylphosphonate group. The hydrophobic ester prodrug can be cleaved to produce a phosphorylated zidovudine in the brain. Due to the charge on phosphorylated zidovudine, it is trapped in the brain. Using this prodrug system, Somogyi and colleagues showed successful penetration of zidovudine into rabbit brain. In another study, Morgan et al. studied the brain penetration of another hydrophilic drug, didanosine. The authors synthesized a series of prodrugs, with a general structure of 6-halo-dideoxypurine. The activation of the prodrug was mediated by the enzyme adenosine deaminase, which is highly expressed in the brain. Upon intravenous injections, all prodrugs led to higher accumulation of didanosine in rat brain. However, due to an optimum balance of hydrophobicity and rate of activation, 6-chloro dideoxypurine showed highest brain accumulation.

Drug transporter-mediated efflux of drugs from the CNS contributes significantly to poor brain delivery. P-gp is one such efflux transporter, and is highly expressed on the blood brain barrier, and actively eliminates drugs from the CNS. There has been significant research in attempting to overcome P-gp mediated drug efflux. This has led to the development of several competitive and allosteric inhibitors of P-gp. Co-delivery of drugs that are P-gp substrates with P-gp inhibitors can potentially improve their delivery to the brain.

In their initial proof-of-concept studies, Choo et al. showed that co-delivery of nelfinavir with an allosteric inhibitor of P-gp (LY335979) could dramatically increase the brain accumulation of the drug. In fact, the brain concentrations of nelfinavir when co-delivered with LY335979 were comparable to those in P-gp knockout animals. Further, delivery of nelfinavir with ritonavir (another P-gp substrate) also led to an improved uptake. This phenomenon was likely due to the competitive binding of ritonavir with P-gp. However, improvement in brain accumulation with LY335979 was more pronounced. Similar results were obtained with co-delivery of nelfinavir with GF120918, another allosteric inhibitor of Pgp. The brain to plasma ratio of nelfinavir in GF120918 treated animals was ~100-fold higher as compared to animals receiving nelfinavir alone. Surfactants such as pluronic 85 are known to be potent inhibitors of efflux transporters. This property has been used significantly for the delivery of anticancer drugs to multi-drug resistant tumors. Spitzenberger and colleagues showed that co-administration of zidovudine, lamivudine and nelfinavir with pluronic 85 led to a significantly improved anti-HIV activity in a HIV-1 induced encephalitis model.

HIV-infected macrophages act as carriers for transporting the virus into the brain. Hence, macrophages show good penetration into the brain, and loading drugs into these
cells may allow their entry into the brain. The Gendelman lab has shown that drug nanoparticles can be loaded into macrophages in vitro, and the drug loaded macrophages can then be injected intravenously. Encapsulation in macrophages results in a prolonged drug half-life, improved drug penetration into the brain and greater antiretroviral activity. Dou et al. loaded surfactant-stabilized indinavir nanoparticles into bone marrow-derived macrophages. When delivered as the free drug or nanoparticle formulations, blood levels of indinavir diminished within a few hours, while macrophage-based delivery resulted in elevated drug levels for 2 weeks. In an HIV-1 induced brain encephalitis model, macrophages entered at sites of inflammation, resulting in higher drug levels in the infected sites of the brain.

5 Future directions

Improving the delivery of HIV drugs can enhance their efficacy. As discussed previously, these strategies can potentially improve patient adherence to therapy and enhance drug concentrations in viral reservoirs. However, there are several limitations to these approaches. In this section, we highlight a few of these issues and provide possible directions for the future development of ARV therapy.

Long-acting injectables have revolutionized our outlook on PrEP, and may possibly impact treatment as well. These nanoparticle-based therapies have reduced dosing frequency from once-daily to once-monthly and potentially longer. However, there are some limitations to this approach. First, this strategy was made possible by the availability of potent drugs that require doses < 50 mg/day. This dose-based limitation is directly related to the total volume that can be administered in a single injection. For example, cabotegravir (daily oral dose - 30 mg) requires 2 injections (2 mL, 200 mg/mL) to achieve its monthly intramuscular dose of 800 mg. Thus, for reasons of feasibility, drugs with daily doses above this value are not good candidates for these formulations. There are very few FDA-approved drugs or drugs in the pipeline that meet this criterion (Tables 1 and 2). Second, drug properties, such as partition coefficient and solubility in physiological fluids, determine their suitability for this approach. If these properties are inappropriate, excipients (such as polymers) are required to modulate drug release. Addition of excipients reduces the total dose that can be administered in a single injection. Alternately, the drug needs to be encapsulated in implantable devices which may require minor surgical procedures. The need for medical procedures limits the use of this approach as well. Hence, there is a tremendous need for the discovery of potent drugs with favorable physicochemical properties.

Another limitation of long-acting injectables is that they need to be injected. In the case of cabotegravir, the dose is split into two intramuscular injections. Pain and discomfort during injection were the major complaints during clinical trials involving these products. While several patients prefer infrequent injections to daily pills, it will be important to monitor patient behavior and preference if these injections are required throughout their life. Alternatively, a long-acting oral dosage form would be very attractive.
This approach combines the advantages of infrequent dosing and the oral route of drug delivery. Discovery of drugs with long half-lives may contribute to this end. Additionally, gastric resident oral drug delivery systems\textsuperscript{175,176} may also be an attractive strategy.

Delivery to viral reservoirs is a significant challenge, which results in incomplete therapy. While several strategies have been developed for improving delivery, several obstacles still remain. For example, inhibitors of drug transporters have limited applicability because of their unfavorable toxicity profile. Nanoparticle-based drug carriers are required to be injected for optimal performance and cell-based drug delivery systems require elaborate \textit{ex vivo} preparation prior to administration. Developing platforms that are economic and easy to implement will be vital for addressing these issues.

6 Conclusion

Despite significant improvements in the treatment of HIV, it continues to be a major health concern. The treatment efficacy with antiretrovirals has not reached its full potential due to the suboptimal use of these drugs. Simplifying dosing regimens and making treatment administration more patient-friendly may encourage appropriate use of drugs. Dosage forms such as long acting dosage forms and polymeric vaginal rings may help achieve this end goal. Complete elimination of viral sanctuaries in HIV-infected patients also poses a significant challenge to HIV therapy. Barriers to drug distribution such as the blood brain barrier, and the inherent physicochemical properties of the drug limit optimum biodistribution of the drug. Nanoparticle- and cell-based drug delivery systems may allow improved penetration of drugs into these viral reservoirs.

In summary, the preceding 3 decades have been notable for the development of a broad range of ARVs. Maximizing their application for effective patient care will lie in significant drug delivery developments in the decades to come.

7 References


### Table 1: List of FDA approved drug*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Route of administration and dose</th>
<th>Year of approval</th>
<th>Terminal half life</th>
<th>clogP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine</td>
<td>NRTI</td>
<td>PO, 300 mg twice a day</td>
<td>1987</td>
<td>0.5-3 h</td>
<td>0.043</td>
</tr>
<tr>
<td>Didanosine</td>
<td>NRTI</td>
<td>PO, 400 mg once a day</td>
<td>1991</td>
<td>1.5 h</td>
<td>-0.33</td>
</tr>
<tr>
<td>Stavudine</td>
<td>NRTI</td>
<td>PO, 40 mg twice a day</td>
<td>1994</td>
<td>1.6 h</td>
<td>-0.49</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>NRTI</td>
<td>PO, 150 mg twice a day or 300 mg once a day</td>
<td>1995</td>
<td>5-7 h</td>
<td>-1.46</td>
</tr>
<tr>
<td>Abacavir</td>
<td>NRTI</td>
<td>PO, 300 mg twice a day or 600 mg once a day</td>
<td>1998</td>
<td>1.5 h</td>
<td>0.81</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>NRTI</td>
<td>PO, 200 mg once a day</td>
<td>2003</td>
<td>10 h</td>
<td>-1.29</td>
</tr>
<tr>
<td>Tenofovir disoproxil</td>
<td>NtRTI</td>
<td>PO, 300 mg once a day</td>
<td>2001</td>
<td>17 h</td>
<td>0.8</td>
</tr>
<tr>
<td>Tenofovir alafenamide</td>
<td>NtRTI</td>
<td>PO, 25 mg once a day</td>
<td>2015</td>
<td>0.5 h (150-180 h for tenofovir diphosphate)</td>
<td></td>
</tr>
<tr>
<td>Nevirapine</td>
<td>NNRTI</td>
<td>PO, for 1st two weeks: 200 mg once a day, after two weeks: 200 mg twice a day</td>
<td>1996</td>
<td>45 h in naïve patients (25-30 h on multiple dosing)</td>
<td>2.65</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>NNRTI</td>
<td>PO, 600 mg once a day</td>
<td>1998</td>
<td>52-76 h after single dose (40-55 h after multiple doses)</td>
<td>3.73</td>
</tr>
<tr>
<td>Etravirine</td>
<td>NNRTI</td>
<td>PO, 200 mg twice a day</td>
<td>2008</td>
<td>41 h</td>
<td>5.07</td>
</tr>
<tr>
<td>Rilpivirine</td>
<td>NNRTI</td>
<td>PO, 25 mg once a day</td>
<td>2011</td>
<td>50 h</td>
<td>5.45</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Protease inhibitor</td>
<td>PO, 1000 mg twice a day with 100 mg ritonavir</td>
<td>1995</td>
<td>Not reported</td>
<td>4.72</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>Protease inhibitor</td>
<td>PO, 600 mg twice a day</td>
<td>1996</td>
<td>3-5 h</td>
<td>4.94</td>
</tr>
<tr>
<td>Indinavir</td>
<td>Protease inhibitor</td>
<td>PO, 800 mg three times a day</td>
<td>1996</td>
<td>1.8 h</td>
<td>3.68</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>Protease inhibitor</td>
<td>PO, 1250 mg twice a day or 750 mg three times a day</td>
<td>1997</td>
<td>3.5-5 h</td>
<td>5.84</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>Protease inhibitor</td>
<td>PO, 300 mg once a day with 100 mg ritonavir or 400 mg once a day alone</td>
<td>2003</td>
<td>6.5 h (8.6 h with ritonavir)</td>
<td>5.92</td>
</tr>
<tr>
<td>Fosamprenavir</td>
<td>Protease inhibitor</td>
<td>PO, 1400 mg twice a day alone or</td>
<td>2003</td>
<td>7.7 h</td>
<td>2.5</td>
</tr>
<tr>
<td>Drug</td>
<td>Class</td>
<td>Dosing Information</td>
<td>Year</td>
<td>t1/2 (h)</td>
<td>ClogP</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------</td>
<td>----------</td>
<td>-------</td>
</tr>
<tr>
<td>Tipranavir</td>
<td>Protease inhibitor</td>
<td>1400 mg once a day with 100 or 200 mg ritonavir</td>
<td>2005</td>
<td>5.5-6</td>
<td>7.76</td>
</tr>
<tr>
<td>Darunavir</td>
<td>Protease inhibitor</td>
<td>PO, 500 mg twice a day with 200 mg ritonavir</td>
<td>2005</td>
<td>15 h with ritonavir</td>
<td>2.89</td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>Entry inhibitor</td>
<td>SC, 90 mg twice a day</td>
<td>2003</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>Maraviroc</td>
<td>Entry inhibitor</td>
<td>PO, 150, 300 or 600 mg based on concomitant medication and renal condition</td>
<td>2007</td>
<td>14-18</td>
<td>3.26</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>Integrase inhibitor</td>
<td>PO, 400 mg twice a day</td>
<td>2007</td>
<td>9</td>
<td>1.16</td>
</tr>
<tr>
<td>Dolutegravir</td>
<td>Integrase inhibitor</td>
<td>PO, 50 mg once a day</td>
<td>2013</td>
<td>14</td>
<td>-0.41</td>
</tr>
<tr>
<td>Elvitegravir</td>
<td>Integrase inhibitor</td>
<td>PO, 85 mg or 150 mg once a day with various protease inhibitors</td>
<td>2014</td>
<td>8.7 h with ritonavir</td>
<td>5.55</td>
</tr>
</tbody>
</table>

*Delavirdine, amprenavir and zalcitabine have been FDA-approved as well, but no longer available in the US, and have not been included in this list.

clogP values were determined using ChemBioDraw Ultra (Perkin Elmer Inc., USA)
All other information was obtained from [https://aidsinfo.nih.gov/](https://aidsinfo.nih.gov/)
<table>
<thead>
<tr>
<th>Drug name</th>
<th>Mechanism</th>
<th>Dose</th>
<th>Clinical Phase</th>
<th>Study identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibalizumab</td>
<td>Entry inhibitor</td>
<td>IV, 800 mg every two weeks or 2000 mg every four weeks</td>
<td>III</td>
<td>NCT02707861</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV, 2000 mg loading dose, followed by 800 mg every two weeks</td>
<td>III</td>
<td>NCT02475629</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV, 800 mg once every two weeks</td>
<td>III</td>
<td>NCT02028819</td>
</tr>
<tr>
<td>PRO-140</td>
<td>Entry inhibitor</td>
<td>Not available</td>
<td>II</td>
<td>NCT01272258</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC, 350 mg every week</td>
<td>II</td>
<td>NCT02438345</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC, 350 mg every week</td>
<td>II/III</td>
<td>NCT02483078</td>
</tr>
<tr>
<td>GS9883</td>
<td>Integrase inhibitor</td>
<td>PO, 50 mg every day</td>
<td>III</td>
<td>NCT02607956</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 50 mg every day</td>
<td>III</td>
<td>NCT02603107</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 50 mg every day</td>
<td>III</td>
<td>NCT02607930</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 50 mg every day</td>
<td>III</td>
<td>NCT02652624</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 50 mg every day</td>
<td>III</td>
<td>NCT02603120</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>Integrase inhibitor</td>
<td>PO, 30 mg every day or IM, 800 mg every 4 weeks</td>
<td>II</td>
<td>NCT02178800</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 30 mg every day or IM, 600 mg every 4 weeks</td>
<td>II/III</td>
<td>NCT02720094</td>
</tr>
<tr>
<td>Cerniviroc</td>
<td>Entry inhibitor</td>
<td>PO, 50 mg every day</td>
<td>II</td>
<td>NCT02128828</td>
</tr>
<tr>
<td>Fostemsavir</td>
<td>Entry inhibitor</td>
<td>PO, 600 mg-1200 mg twice every day</td>
<td>I</td>
<td>NCT02674581</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 600 mg twice daily</td>
<td>III</td>
<td>NCT02362503</td>
</tr>
<tr>
<td>Epigallocatechin gallate</td>
<td>Entry inhibitor</td>
<td>Not available</td>
<td>I</td>
<td>NCT01433289</td>
</tr>
<tr>
<td>Triptolide woldifii</td>
<td>Degrades Tat protein</td>
<td>Not available</td>
<td>III</td>
<td>NCT02219672</td>
</tr>
<tr>
<td>BMS-955176</td>
<td>Maturation inhibitor</td>
<td>PO, 120 mg daily</td>
<td>II</td>
<td>NCT02386098</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 240 mg</td>
<td>I</td>
<td>NCT02576119</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not available</td>
<td>I</td>
<td>NCT02715479</td>
</tr>
<tr>
<td>Doravirine</td>
<td>NNRTI</td>
<td>PO, 100 mg daily</td>
<td>III</td>
<td>NCT02397096</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 100 mg daily</td>
<td>II</td>
<td>NCT02652260</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO, 100 mg daily</td>
<td>II</td>
<td>NCT02629822</td>
</tr>
<tr>
<td>Drug</td>
<td>Type</td>
<td>Route</td>
<td>Dose/Weekly</td>
<td>Stage</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------</td>
<td>-------</td>
<td>-------------</td>
<td>-------</td>
</tr>
<tr>
<td>Albuvirtide</td>
<td>Entry inhibitor</td>
<td>IV</td>
<td>320 mg</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>every week</td>
<td></td>
</tr>
<tr>
<td>ABX464</td>
<td>Enhances viral RNA splicing</td>
<td>PO</td>
<td>50 mg</td>
<td>II</td>
</tr>
<tr>
<td>MK-8591</td>
<td>Nucleoside reverse transcriptase translocation inhibitor</td>
<td>PO</td>
<td>1-30 mg</td>
<td>I</td>
</tr>
</tbody>
</table>